Home Endocrinology & Hormones Androgen Receptor antagonist Bicalutamide

연구용

Bicalutamide Androgen Receptor antagonist

제품 번호: S1190

Bicalutamide is an androgen receptor (AR) antagonist with IC50 of 0.16 μM in LNCaP/AR(cs)cell line. This compound promotes autophagy.
Bicalutamide Androgen Receptor antagonist Chemical Structure

화학 구조

분자량: 430.37

바로가기

품질 관리 (Quality Control)

배치: 순도: 99.98%
99.98

세포 배양, 처리 및 작업 농도
(Cell Culture, Treatment & Working Concentration)

세포주 분석 유형 농도 배양 시간 제형 활성 설명 PMID
human MDA-MB-453 cells Function assay Displacement of [3H]R1881 from AR in human MDA-MB-453 cells, EC50=31 nM
LNCaP cells Function assay Inhibition of [3H]-DHT binding to T877A androgen receptor of LNCaP cells, Ki=35 nM
Freestyle293F cells Function assay Inhibition of wild type Androgen receptor (unknown origin) expressed in Freestyle293F cells, IC50=0.054 μM
HEK293 cells Function assay 3 h Displacement of [17-alpha-methyl-3H]mibolerone from androgen receptor expressed in HEK293 cells after 3 hrs, IC50=54 nM
MDA453 cells Function assay Displacement of [3H]DHT from human androgen receptor in MDA453 cells, Ki=64 nM
human MDA-MB-453 cells Function assay Displacement of [3H]DHT from AR in human MDA-MB-453 cells, IC50=64 nM
COS1 cells Function assay Antagonist activity against pSG5-tagged human androgen receptor expressed in COS1 cells assessed as reduction in receptor-mediated transcriptional activity by AR-regulated rat probasin promoter fragment driven firefly luciferase reporter assay, IC50=0.0869 μM
HeLa cells Function assay Antagonist activity at human androgen receptor expressed in HeLa cells assessed as inhibition of dihydrotestosterone induced transcriptional activity by reporter gene assay, IC50=0.14 μM
CV1 cells Function assay Binding affinity to human androgen receptor expressed in CV1 cells, Ki=0.151 μM
monkey COS7 cells Function assay Binding affinity to human androgen receptor expressed in monkey COS7 cells by whole cell binding assay, Ki=0.151 μM
COS7 cells Function assay Agonist activity at human androgen receptor W741C mutant expressed in COS7 cells assessed as luciferase activity after 24 hrs by reporter gene assay, EC50=0.18 μM
CHO-K1 cells Function assay 2 h Displacement of [3H]mibolerone from human AR expressed in CHO-K1 cells after 2 hrs by scintillation counting, IC50=0.2 μM
human HT-3 cell Growth inhibition assay Inhibition of human HT-3 cell growth in a cell viability assay, IC50=0.73134 μM
human LNCAP cells Proliferation assay 3 days Antiproliferative activity against human LNCAP cells after 3 days, IC50=0.7327 μM
human PC3 cells Function assay Displacement of [3H]R1881 from androgen receptor in human PC3 cells, EC50=4.3 μM
human 22Rv1 cells Function assay 3 days Antagonist activity at androgen receptor H874Y mutant (unknown origin) expressed in human 22Rv1 cells assessed as inhibition of DHT-induced cell growth after 3 days by WST-8 assay, IC50=4.6 μM
human CCF-STTG1 cell Growth inhibition assay Inhibition of human CCF-STTG1 cell growth in a cell viability assay， IC50=4.92929 μM
human SCC-25 cell Growth inhibition assay Inhibition of human SCC-25 cell growth in a cell viability assay, IC50=6.08656 μM
human MKN45 cell Growth inhibition assay Inhibition of human MKN45 cell growth in a cell viability assay, IC50=6.9605 μM
human ES5 cell Growth inhibition assay Inhibition of human ES5 cell growth in a cell viability assay, IC50=8.61154 μM
human SK-MEL-3 cell Growth inhibition assay Inhibition of human SK-MEL-3 cell growth in a cell viability assay, IC50=10.0964 μM
human PC-3 cell Growth inhibition assay Inhibition of human PC-3 cell growth in a cell viability assay, IC50=10.2791 μM
human NOS-1 cell Growth inhibition assay Inhibition of human NOS-1 cell growth in a cell viability assay, IC50=11.2917 μM
human LB1047-RCC cell Growth inhibition assay Inhibition of human LB1047-RCC cell growth in a cell viability assay, IC50=12.253 μM
human CAMA-1 cell Growth inhibition assay Inhibition of human CAMA-1 cell growth in a cell viability assay, IC50=12.3926 μM
human SAS cell Growth inhibition assay Inhibition of human SAS cell growth in a cell viability assay, IC50=13.3081 μM
human NCI-H2228 cell Growth inhibition assay Inhibition of human NCI-H2228 cell growth in a cell viability assay, IC50=13.7531 μM
human NCI-H187 cell Growth inhibition assay Inhibition of human NCI-H187 cell growth in a cell viability assay, IC50=16.6616 μM
human BFTC-905 cell Growth inhibition assay Inhibition of human BFTC-905 cell growth in a cell viability assay, IC50=17.4857 μM
human G-361 cell Growth inhibition assay Inhibition of human G-361 cell growth in a cell viability assay, IC50=17.826 μM
human DU145 cells Cytotoxic assay 72 h Cytotoxicity against ERalpha-deficient human DU145 cells expressing ERbeta assessed as growth inhibition after 72 hrs by MTT assay, IC50=18 μM
human SW780 cell Growth inhibition assay Inhibition of human SW780 cell growth in a cell viability assay
human BB49-HNC cell Growth inhibition assay Inhibition of human BB49-HNC cell growth in a cell viability assay, IC50=18.9532 μM
human KALS-1 cell Growth inhibition assay Inhibition of human KALS-1 cell growth in a cell viability assay, IC50=19.6635 μM
human AU565 cell Growth inhibition assay Inhibition of human AU565 cell growth in a cell viability assay, IC50=19.7402 μM
human NCI-H2087 cell Growth inhibition assay Inhibition of human NCI-H2087 cell growth in a cell viability assay, IC50=21.0591 μM
human RVH-421 cell Growth inhibition assay Inhibition of human RVH-421 cell growth in a cell viability assay, IC50=21.5795 μM
human SK-CO-1 cell Growth inhibition assay Inhibition of human SK-CO-1 cell growth in a cell viability assay, IC50=21.8872 μM
human KU-19-19 cell Growth inhibition assay Inhibition of human KU-19-19 cell growth in a cell viability assay, IC50=22.0242 μM
human NB6 cell Growth inhibition assay Inhibition of human NB6 cell growth in a cell viability assay, IC50=22.9135 μM
human RO82-W-1 cell Growth inhibition assay Inhibition of human RO82-W-1 cell growth in a cell viability assay, IC50=23.1318 μM
human LNCAP cells Cytotoxic assay 2 days Cytotoxicity against human LNCAP cells assessed as cell viability after 2 days by cell counting method, IC50=23.79 μM
human CTB-1 cell Growth inhibition assay Inhibition of human CTB-1 cell growth in a cell viability assay, IC50=24.5536 μM
human SW48 cell Growth inhibition assay Inhibition of human SW48 cell growth in a cell viability assay, IC50=24.6546 μM
human TCCSUP cell Growth inhibition assay Inhibition of human TCCSUP cell growth in a cell viability assay, IC50=24.7232 μM
human DK-MG cell Growth inhibition assay Inhibition of human DK-MG cell growth in a cell viability assay, IC50=24.8917 μM
human ST486 cell Growth inhibition assay Inhibition of human ST486 cell growth in a cell viability assay, IC50=25.7464 μM
human H4 cell Growth inhibition assay Inhibition of human H4 cell growth in a cell viability assay, IC50=26.9458 μM
human SBC-1 cell Growth inhibition assay Inhibition of human SBC-1 cell growth in a cell viability assay, IC50=28.3507 μM
human CAS-1 cell Growth inhibition assay Inhibition of human CAS-1 cell growth in a cell viability assay, IC50=28.6294 μM
human OAW-42 cell Growth inhibition assay Inhibition of human OAW-42 cell growth in a cell viability assay, IC50=28.7195 μM
human HCC1954 cell Growth inhibition assay Inhibition of human HCC1954 cell growth in a cell viability assay, IC50=28.7525 μM
human MDA-MB-453 cell Growth inhibition assay Inhibition of human MDA-MB-453 cell growth in a cell viability assay, IC50=29.907 μM
human MCF7 cell Growth inhibition assay Inhibition of human MCF7 cell growth in a cell viability assay, IC50=39.301 μM
human PC3 cells Function assay 100　μM 48 h Inhibition of actin based pseudopodia formation in androgen-dependent human PC3 cells at 100 uM after 48 hrs by DAPI staining based fluorescence microscopy assay
human PC3 cells Function assay 0.1-1 μM Agonist activity at androgen receptor W741C mutant expressed in human PC3 cells assessed as stimulation of receptor transactivation at 0.1 to 1 uM by luciferase reporter gene assay
클릭하여 더 많은 세포주 실험 데이터 보기

화학 정보, 보관 및 안정성 (Chemical Information, Storage & Stability)

분자량 430.37 화학식

C18H14F4N2O4S

 보관 (수령일로부터)
CAS 번호 90357-06-5 SDF 다운로드 원액 보관

동의어 ICI-176334 Smiles CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O

용해도 (Solubility)

In vitro
배치:

DMSO : 86 mg/mL (199.82 mM)
(수분으로 오염된 DMSO는 용해도를 감소시킬 수 있습니다. 신선하고 무수 DMSO를 사용하십시오.)

Ethanol : 7 mg/mL

Water : Insoluble

몰농도 계산기

질량 농도 부피 분자량
희석 계산기 분자량 계산기

In vivo
배치:

생체 내 제형 계산기 (투명한 용액)

1단계: 아래 정보 입력 (권장: 실험 중 손실을 고려하여 추가 동물 포함)

mg/kg g μL

2단계: 생체 내 제형 입력 (이것은 계산기일 뿐 제형이 아닙니다. 용해도 섹션에 생체 내 제형이 없는 경우 먼저 당사에 문의하십시오.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

계산 결과:

작업 농도: mg/ml;

DMSO 원액 준비 방법: mg 약물 사전 용해 μL DMSO ( 원액 농도 mg/mL, 농도가 해당 약물 배치의 DMSO 용해도를 초과하는 경우 먼저 당사에 문의하십시오. )

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가μL PEG300, 혼합하고 투명하게 한 다음 추가μL Tween 80, 혼합하고 투명하게 한 다음 추가 μL ddH2O, 혼합하고 투명하게 합니다.

생체 내 제형 준비 방법: 취하다 μL DMSO 원액, 다음 추가 μL 옥수수 기름, 혼합하고 투명하게 합니다.

참고: 1. 다음 용매를 추가하기 전에 액체가 투명한지 확인하십시오.
2. 용매를 순서대로 추가해야 합니다. 다음 용매를 추가하기 전에 이전 추가에서 얻은 용액이 투명한 용액인지 확인해야 합니다. 와동, 초음파 또는 뜨거운 물 중탕과 같은 물리적 방법을 사용하여 용해를 도울 수 있습니다.

작용 메커니즘 (Mechanism of Action)

Targets/IC50/Ki
Androgen Receptor
(LNCaP/AR(cs) cells)
0.16 μM
시험관 내(In vitro)
Bicalutamide undergoes an antagonist-to-agonist switch, stimulating AR activity. This compound treatment of LNCaP/AR(cs) cells in absence of the synthetic androgen R1881 results in altered gene expression consistent with its well-documented agonist activity in context of AR overexpression. It induces cell proliferation in a dose-dependent manner, and only partially antagonized the effects of R1881. This chemical treatment also results in a significant amount of nuclear AR, although less than that observed with R1881. It exhibits partial agonist activity as evidenced by induction of DNA binding at AR target genes and incomplete antagonism of the effects of R1881. In absence of R1881, this agent partially activates VP16-AR–mediated transcription, indicative of AR binding to DNA. In LNCaP/AR-luc cells with a stably integrates AR-driven luciferase reporter construct. In the presence of R1881, it shows only weak partial antagonism of VP16-AR–mediated transcription with an IC50 of 0.35 μM. Micromolar bicalutamide causes a significant dose-dependent reduction in clonogenicity. Dual inhibition of the AR and mTOR signaling pathways provides further benefit with the ridaforolimus-this compound combination producing syner -gistic antiproliferative effects in prostate cancer cells in vitro when compared with each agent alone.
키나아제 분석
Whole-cell competitive binding assays
Whole-cell competitive binding assays are performed in LNCaP/AR(codon-switch) (LNCaP/AR(cs)) (harbors a mixture of exogenous wild-type AR and endogenous mutant AR (T877A)) and cells propagated in Iscove's or RPMI media supplemented with 10% fetal bovine serum, or during the assay with 10% charcoal-stripped, dextran-treated fetal bovine serum (CSS). Cells are pre-incubated with 18F-FDHT, increasing concentrations (1pM to 1μM) of cold this compound are added, and the assay is performed to measure specific uptake of 18F-FDHT (4). IC50 values are determined using a one site binding model with least squares curve fitting and R2 > 0.99.
생체 내(In vivo)
Single bicalutamide reduces tumor growth by 79%, at defined submaximal doses. The ridaforolimus-this compound combination exhibits improved and potent antitumor activity, almost completely abrogating tumor growth. The combination is also well tolerated, as evidenced by no significant changes in body weight over the course of treatment. Plasma PSA levels are again tightly linked to tumor growth in the combination-treated mice.
참조

적용 분야 (Applications)

방법 바이오마커 이미지 PMID
Western blot Cytosolic AR / Nuclear AR
S1190-WB1
30833616
Growth inhibition assay Cell viability
S1190-viability1
27994514

임상시험 정보 (Clinical Trial Information)

(데이터 출처 https://clinicaltrials.gov, 업데이트 날짜 2024-05-22)

NCT 번호 모집 조건 스폰서/협력자 시작일 단계
NCT06222593 Not yet recruiting
Carcinoma Renal Cell
State University of New York at Buffalo
 June 1 2024 Phase 1|Phase 2
NCT04573231 Recruiting
Breast Cancer|HER2-negative Breast Cancer|Metastatic Breast Cancer
University of Wisconsin Madison
 May 24 2021 Phase 2
NCT04443062 Recruiting
Prostate Cancer
Radboud University Medical Center|Prostaatkankerstichting|Advanced Accelerator Applications
 July 20 2020 Phase 2
NCT02910050 Unknown status
Breast Cancer
Xu fei|Sun Yat-sen University
 January 2016 Phase 2